股票行情快报：五洲医疗（301234）2月5日主力资金净卖出56.86万元

Core Viewpoint - Five Continents Medical (301234) reported a slight increase in stock price but faced significant declines in net profit and net profit after deducting non-recurring gains in the third quarter of 2025 [1][2]. Financial Performance - For the first three quarters of 2025, the company's main revenue was 345 million yuan, a year-on-year increase of 0.82% [2]. - The net profit attributable to shareholders was 18.51 million yuan, a year-on-year decrease of 46.09% [2]. - The net profit after deducting non-recurring gains was 14.82 million yuan, a year-on-year decrease of 45.3% [2]. - In the third quarter of 2025, the company's single-quarter main revenue was 128 million yuan, a year-on-year decrease of 1.51% [2]. - The single-quarter net profit attributable to shareholders was 7.99 million yuan, a year-on-year decrease of 36.39% [2]. - The single-quarter net profit after deducting non-recurring gains was 6.48 million yuan, a year-on-year decrease of 28.01% [2]. - The company's debt ratio was 12.32%, with investment income of 3.67 million yuan and financial expenses of -2.07 million yuan [2]. - The gross profit margin was 14.22% [2]. Business Model - Five Continents Medical specializes in the research, production, and sales of disposable sterile infusion medical devices, as well as integrated supply of other diagnostic and nursing medical supplies [2]. - The company primarily operates through an "ODM + integrated supply" model to meet the one-stop procurement needs of foreign medical device brand owners [2].